Aptose To Release Second Quarter Ended June 30, 2018 Financial Results and Hold Conference Call on August 7, 2018
Aptose Biosciences, Inc.
Jul. 24, 2018
SAN DIEGO and TORONTO, July 24, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, will release its financial results for the quarter ended June 30, 2018 on Tuesday, August 7, 2018 at 5:00 pm Eastern time.
Conference Call & Webcast: Tuesday, August 7, 2018 @ 5:00 pm Eastern time Toll-Free: (844) 882-7834 International: (574) 990-9707 Passcode: 2693419 Webcast: https://edge.media-server.com/m6/p/8qrt4qyn Replays available through August 14, 2018 Toll-Free: (855) 859-2056 Replay Passcode: 2693419
The live conference call can also be accessed through a link on the Investor Relations section of Aptose’s website at ir.aptose.com. Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. An archived version of the webcast along with a transcript will be available on the company’s website for 30 days.
The press release, the financial statements and the management’s discussion and analysis for the quarter ended June 30, 2018 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml
About Aptose Biosciences Inc.
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. APTO-253, the only clinical stage inhibitor of MYC oncogene expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk MDS. CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-cluster kinase inhibitor expected to reach IND submission by the end of 2018 and is planned for development to treat AML and certain B cell malignancies. For further information, please visit www.aptose.com.
For further information, please contact:
Aptose Biosciences Greg Chow, CFO 647-479-9828 Email: firstname.lastname@example.org SMP Communications LifeSci Advisors Susan Pietropaolo Michael Wood 201-923-2049 Managing Director email@example.com 646-597-6983 firstname.lastname@example.org